Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
5 to 70 in 14 months is a BEAST..probably caused at least some shorts to jump off bridges
do you have to post bookmarked?
I think the 20's
what was the price when we added it to the MAG7
pcyc is a beast. check out srpt. i'm in since $7.50. could be the next alxn
continues to amaze me......and that is hard to do
.....Ron you should become a MOD here!!!!!!!!!!!!!
>>> Pharmacyclics Earns Milestone
By Zacks Equity Research
Aug 24, 2012
http://finance.yahoo.com/news/pharmacyclics-earns-milestone-185935099.html
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase II study that is being conducted with ibrutinib in patients suffering from relapsed or refractory mantle cell lymphoma (:MCL). With the enrollment of the fifth patient, Pharmacyclics is eligible to receive a $50 milestone payment from partner, Janssen Biotech, Inc., a Johnson & Johnson (JNJ) company.
The single-arm, multi-center phase II study, SPARK (MCL2001), is being conducted in MCL patients who have been treated with at least one prior rituximab-containing chemotherapy regimen and who progressed after treatment with bortezomib. While overall response rate is the primary endpoint, secondary endpoints include overall survival rate, progression-free survival rate, and pharmacokinetic data.
Pharmacyclics and Janssen’s agreement dates back to December 2011. The companies are collaborating for the global development and commercialization of ibrutinib. Besides receiving a $150 million upfront payment from Janssen, Pharmacyclics is entitled to receive another $825 million on the achievement of development and regulatory milestones.
With the triggering of the $50 million milestone payment for the SPARK study, Pharmacyclics has already earned $100 million in the form of development milestones. This includes a $50 million milestone payment that was triggered earlier this month with the enrollment of the fifth patient in another study (RESONATE (PCYC-1112)) with ibrutinib.
The international phase III randomized, multicenter, open-label RESONATE study is being conducted in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
We currently have a Neutral recommendation on Pharmacyclics, which carries a Zacks #2 Rank (short-term ‘Buy’ rating). We are positive on the company’s collaboration with Janssen for ibrutinib. Janssen is a suitable partner for Pharmacyclics. Janssen’s strong global presence bodes well for the commercialization of ibrutinib, once it is approved.
<<<
6:31AM Pharmacyclics triggers milestone payment and provides clinical program update (PCYC) 53.21 : Co announced that the international Phase III randomized, multicenter, open-label clinical trial, RESONATE (PCYC-1112), of ibrutinib versus ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) initiated by Pharmacyclics has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a $50 mln milestone payment obligation from Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) and the worldwide collaborator on ibrutinib in oncology. As Pharmacyclics or Janssen initiate further Phase III trials in specific indications and enroll the 5th patient, additional milestone payments of $50 mln may be triggered up to a total of $250 mln. Co anticipates an additional Phase III trial milestone payment during calendar 2013. Pharmacyclics and Janssen plan to initiate three additional Phase III studies over the next 6 - 9 months. These studies include Phase III combination study of bendamustine/rituximab plus ibrutinib versus bendamustine/rituximab plus placebo in relapsed or refractory CLL/SLL patients, Phase III frontline study of single agent ibrutinib versus a comparator in elderly CLL/SLL patients, and a Phase III study outside the US of ibrutinib versus temsirolimus in subjects with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior chemotherapy regimen
take your basis off the table at $180 LMAO...nothing goes up forever
Chronic lymphocytic leukemia, or CLL, is a type of cancer. CLL is the most common chronic leukemia in the United States. In fact, over 15,000 new cases of CLL are expected each year. For some people with CLL, the disease grows so slowly they may not need treatment.
what is the OS here?
Wedburg put an $80 target on PCYC when it was trading around $25. Some thought they were being ridiculous. Now some could argue $80 is a low target
this stock may get to 100 before I get thru scratching my arse
no kidding...posted at 51 now its 60 a few post later. If I had an 18 basis like you I would post a HOT DIGGETTY DAMN every dollar
Pharmacyclics (PCYC) is a stock creating 52-week highs on a daily basis, thanks to its one-month return of 57%. The $3.5 billion company has been on a tear in 2012, with a YTD gain of 250%. The company's pipeline of small-molecule drugs are creating quite a buzz, and thanks to heavy insider buying the stock has performed nicely for anyone who has ever purchased shares in this company.
http://seekingalpha.com/article/683601-8-biotechnology-stocks-trading-higher-despite-market-volatility?source=yahoo
used to be quiet.........You and I are here....and after we invite a few friends.......I will bet we have GEOMETRIC growth
Yeah honestly I wouldn't be surprised
No, this board is very quiet so I didn't post. I follow the yahoo board since there is more active.
I thought you have more posts here RON...were some deleted?
Progression free survival with a median follow-up of 14.4 months is 96%
what is the name for that...oh yeah OVERWHELMING EFFICACY
....HMMMMMMMM maybe an IDEAL test case for the NEW authority FDA has under the NEW PDUFA act?hmmmmmmmmmmmmmm
Enjoy your quiet time here posters.......soon this will be a BOILING place filled with madness...10K posts and 1000 posters
Dont laugh about the 100 call......you may get there before the leaves fall
Wow what the hell is the target here :)
$45.................................................................
12:38AM Pharmacyclics provides updated results for BTK inhibitor Ibrutinib (PCYC) 41.23 : Co provides results from two clinical trials of Bruton's tyrosine kinase inhibitor, ibrutinib, for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. The ibrutinib clinical updates at EHA released in two oral presentations include: 1) updated safety and efficacy data from the Phase Ib/II CLL/SLL single agent trial (PCYC-1102); and 2) updated safety and efficacy data from the Phase Ib/II CLL/SLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108). Highlights of study 1 include: (-) Non-hematologic toxicities of ibrutinib single agent remain manageable and tolerable with no new signals; hematologic toxicities were uncommon. (-) PFS with a median follow-up of 17.5 months is 87.7% in the relapsed/refractory 420 mg cohort. (-) High risk relapsed/refractory patients with 17p deletion and IgVH unmutated status, have an estimated 18-month PFS of >70% and >80%, respectively. (-) As previously presented, in the treatment naive patients, overall response rate in the 420 mg cohort is 81% using ibrutinib as a single agent. 12% of patients achieved a complete response with no morphologic evidence of CLL. Progression free survival with a median follow-up of 14.4 months is 96% in the 420 mg cohort. The Second study highlights include: (-) Adverse events are consistent with previous reports of the BR and FCR combination. No new safety signals with the combination of ibrutinib and BR were identified. (-) As previously presented at ASCO, overall response rate with BR is 93%, with 13% of patients achieving a complete response with no morphologic evidence of CLL. (-) At 8.5 months of median follow-up all three patients that received ibrutinib in combination with FCR remain progression free with two achieving minimal residual disease negative complete responses.
ouch!!!!! $40s....... weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
6:09AM Pharmacyclics beats by $0.06, misses on revs (PCYC) 26.80 : Reports Q3 (Mar) loss of $0.14 per share, $0.06 better than the Capital IQ Consensus Estimate of ($0.20); revenues fell 6.3% year/year to $1.93 mln vs the $3.91 mln consensus.
Yes, very bullish but the article is from March 27th
News Breaks March 27, 2012
08:42 EDT PCYC
theflyonthewall.com: Pharmacyclics target raised to $42 from $21 at Roth Capital
After Pharmacyclics disclosed information about its ibrutinib drug, Roth Capital thinks that the market potential for the lymphoma treatment is "quite large." The firm is impressed by the speed of the clinical program for the drug, and it maintains a Buy rating. :theflyonthewall.com
smart move. this move today will cause a pop early am and then probably sell off midday. ill be holding my freebies for a little longer. with the low float it has, big news will send it into orbit.
I pulled out at $23.25 at the close. My logical side tells me it has to breath a little after 10% day then 17% day in a row.
Looking to reenter around $20 early next week.
WOW congrats. i let some calls go when this was near 23.50, riding free here. what a move!!!
I am holding $13s :)
Pharmacyclics rises after posting 2Q profit
Pharmacyclics turns 2nd-quarter profit after starting J&J collaboration, and shares jump
Associated PressAssociated Press – 19 hours ago
RELATED QUOTES
Symbol Price Change
JNJ 64.51 -0.38
PCYC 22.34 +2.54
SUNNYVALE, Calif. (AP) -- Drug developer Pharmacyclics Inc. said Thursday it turned a profit in the fiscal second quarter after beginning a collaboration with Johnson & Johnson, sending its shares higher.
In December, the company said it would work with a division of Johnson & Johnson to develop a potential treatment for cancers like lymphoma and leukemia. Janssen Pharmaceutical agreed to pay Pharmacyclics $150 million upfront, and if development is successful, Pharmacyclics could get more than $1 billion.
Pharmacyclics said it earned $56.3 million, or 78 cents per share, over the three months ended Dec. 31. Excluding certain items it earned 82 cents per share. A year earlier it took a loss of $7.5 million, or 13 cents per share. Revenue surged to $77.9 million from $2.8 million on higher license and milestone revenue.
Analysts expected the company to report a loss of 19 cents per share and $2.9 million in revenue, according to FactSet.
Shares of Pharmacyclics gained $1.81, or 10.1 percent, to $19.80 while the broader markets ended trading up less than 1 percent.
hahah i just wish I bought the low $19's like you told me to.. damn nice call
I am vomiting in happiness
RUNAWAY TRAIN...
23.33 +3.532 (+17.84%)
thnx joe. lock it up...lolzzz
nice call dude.. that pig is flying today!
WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
22.39 +2.592 (+13.09%)
She sure wants that $25 mark
and another new high!!!
breakthrough!
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
197
|
Created
|
12/19/05
|
Type
|
Free
|
Moderators |
http://finance.yahoo.com/q/ks?s=PCYC+Key+Statistics
Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company's principal development products include Xcytrin injection, an anti-cancer agent that is in phase II clinical trials; and Histone Deacetylase Inhibitor, a phase I clinical trial product that targets histone deacetylase enzymes and inhibits their function. Its other development products comprise HDAC-8 selective inhibitor, a preclinical stage drug for the treatment of cancer; a small molecule inhibitor of Factor VIIa, which has demonstrated anti-angiogenic and anti-cancer activity in the laboratory and inhibitors of tyrosine kinase enzymes; and B cell associated tyrosine kinase inhibitors for the treatment of lymphomas and autoimmune diseases. The company has a collaboration and license agreement with the National Cancer Institute. Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, California.
We are leveraging our small-molecule drug development expertise to build a pipeline in oncology and immune mediated diseases based on novel targets, pathways and mechanisms. We have several products in the pipeline, each derived from structure-based research. Multiple histone deacetylase (HDAC) inhibitors, both broad spectrum (PCI-24781) - meaning they target all forms of HDAC enzymes - and isoform selective (HDAC8), are being developed for solid tumors and lymphomas. Our Factor VIIa inhibitor, PCI-27483, possesses a novel mechanism of action that targets both the tumor itself and thrombotic disease that often occurs in patients with cancer. Finally, our lead BTK inhibitor PCI-32765 shows promising activity in animal models of lymphoma and rheumatoid arthritis.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |